| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/15/2009 | CA2532596C Anti-inflammatory formulations |
| 09/15/2009 | CA2524709C Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors |
| 09/15/2009 | CA2522323C 3-azabicyclo[3.2.1]octane derivatives as opioid receptor ligands |
| 09/15/2009 | CA2512952C Depigmentation agents |
| 09/15/2009 | CA2503154C A new crystalline form of the sodium salt of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid |
| 09/15/2009 | CA2473991C Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor |
| 09/15/2009 | CA2467805C Novel chromium (iii) alpha amino acid complexes |
| 09/15/2009 | CA2464289C Heterocyclic retinoid compounds |
| 09/15/2009 | CA2463583C Highly compressible ethylcellulose for tableting |
| 09/15/2009 | CA2440650C Photosensitizer and method for production thereof |
| 09/15/2009 | CA2439879C C2,5'-disubstituted and n6,c2,5'-trisubstituted adenosine derivatives and their different uses |
| 09/15/2009 | CA2434393C Heparin with average molecular mass |
| 09/15/2009 | CA2429220C Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity |
| 09/15/2009 | CA2419397C Novel use of a peptide class of compound for treating non neuropathic inflammatory pain |
| 09/15/2009 | CA2415752C Novel disaccharides with anti-arthritic action |
| 09/15/2009 | CA2415065C Oral compositions comprising host-response modulating agent |
| 09/15/2009 | CA2411233C Use of hyaluronidase for preventing and treating cardio vascular diseases |
| 09/15/2009 | CA2409819C Triazole derivatives |
| 09/15/2009 | CA2408417C Local anesthetic methods and kits |
| 09/15/2009 | CA2407754C Prodrugs of hiv replication inhibiting pyrimidines |
| 09/15/2009 | CA2406562C Hiv replication inhibiting pyrimidines and triazines |
| 09/15/2009 | CA2402390C Process for the preparation of pyrimidone derivatives with antifungal activity |
| 09/15/2009 | CA2400155C A novel crystalline form of n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and process therefor |
| 09/15/2009 | CA2395774C New polymorphic forms of olanzapine |
| 09/15/2009 | CA2393483C Stable pharmaceutical preparations comprising a benzimidazole and process for their production |
| 09/15/2009 | CA2379696C Inhibition of renal uptake of radiomolecules with a combination of lysine and arginine |
| 09/15/2009 | CA2376835C Condensed imidazole compounds and a therapeutic agent for diabetes mellitus |
| 09/15/2009 | CA2374902C Aminoalkyl substituted benzopyran derivatives for treating impaired fundic relaxation |
| 09/15/2009 | CA2374471C Therapeutically and/or nutritionally enhanced derivatives of active ingredients and orally administrable compositions containing same |
| 09/15/2009 | CA2372560C Cyanopyrroles for binding the progesterone receptor |
| 09/15/2009 | CA2369616C Somatic transgene immunization and related methods |
| 09/15/2009 | CA2364665C Phenyl- and pyridinyl derivatives |
| 09/15/2009 | CA2362363C Substituted 4-amino-2-aryltetrahydroquinazolines, their preparation, their use and pharmaceutical compositions comprising them |
| 09/15/2009 | CA2359463C Novel polyhydroxypyrazine derivatives, preparation and pharmaceutical compositions containing same |
| 09/15/2009 | CA2342985C Hydroxamate-containing cysteine and serine protease inhibitors |
| 09/15/2009 | CA2340021C Use of ginkgo biloba extracts for preparing a medicine for treating amyotrophic lateral sclerosis |
| 09/15/2009 | CA2336952C 5-thia-.omega.-substituted phenyl-prostaglandin e derivatives, process for producing the same and drugs containing the same as the active ingredient |
| 09/15/2009 | CA2334675C Control of parasitic infestations in farmed and wild fish |
| 09/15/2009 | CA2331471C Compounds with an antioxidant activity, compositions useful as food integrators containing them and process for their preparation |
| 09/15/2009 | CA2330330C Pharmaceutical compositions comprising an amphoteric surfactant an alkoxylated cetyl alcohol and a polar drug |
| 09/15/2009 | CA2323111C New substituted indolinones, the preparation thereof and their use as pharmaceutical compositions |
| 09/15/2009 | CA2309100C Lovastatin compositions derived from red rice fermentation products, fermentation processes and monascus strains therefor |
| 09/15/2009 | CA2294086C Palatable elemental medical food |
| 09/15/2009 | CA2274204C Spiro[piperidine-4,1'-pyrrolo[3,4-c]pyrrole] |
| 09/15/2009 | CA2255052C Sustained release preparation of prostaglandin i derivatives |
| 09/15/2009 | CA2218699C 1,3-propane diol derivatives as bioactive compounds |
| 09/15/2009 | CA2218561C Compounds and methods of use to treat infectious diseases |
| 09/15/2009 | CA2204433C Use of neurite localized mrnas for medical diagnosis and therapeutics |
| 09/15/2009 | CA2195396C Genetic diagnosis of prostate cancer |
| 09/15/2009 | CA2168923C Process for the enzymatic synthesis of .beta.-lactam antibiotics in the presence of an enzyme inhibitor |
| 09/15/2009 | CA2168203C Medicinal for protection from neurological damage |
| 09/15/2009 | CA2156272C Dna encoding a human neuropeptide y/peptide yy/pancreatic polypeptide receptor (y4) and uses thereof |
| 09/15/2009 | CA2148871C Method of preventing hyperproliferative vascular disease |
| 09/14/2009 | CA2640954A1 Hepatitis c virus inhibitors |
| 09/11/2009 | WO2009111793A2 Subdermal tissue remodeling using myostatin, methods and related systems |
| 09/11/2009 | WO2009111787A2 ANTAGONISM OF PGF 2α RECEPTOR TO TREAT HYPERTENSION CHARACTERIZED BY ACTIVATION OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM |
| 09/11/2009 | WO2009111785A2 Treatment of sepsis with 5-ethyl-1-phenyl-2(1h)-pyridone and novel methods for synthesis |
| 09/11/2009 | WO2009111739A2 Treatment of herpes virus related diseases |
| 09/11/2009 | WO2009111700A2 Oxadiazoanthracene compounds for the treatment of diabetes |
| 09/11/2009 | WO2009111698A1 Improved anticancer treatments |
| 09/11/2009 | WO2009111695A1 Methods of increasing epidermal skin thickness by topical administration of a 19-nor containing vitamin d compound |
| 09/11/2009 | WO2009111691A2 Combination therapy with c-met and egfr antagonists |
| 09/11/2009 | WO2009111688A2 All-trans retinoid esters as active pharmaceutical ingredients, oral and topical dosage form compositions thereof, and methods of treating skin conditions thereof |
| 09/11/2009 | WO2009111680A1 Trpv4 antagonists |
| 09/11/2009 | WO2009111676A2 Boron-containing small molecules as anti-inflammatory agents |
| 09/11/2009 | WO2009111653A2 Antiviral therapeutic agents |
| 09/11/2009 | WO2009111648A1 Compositions and methods for mucositis and oncology therapies |
| 09/11/2009 | WO2009111638A1 Compositions and methods for drug delivery |
| 09/11/2009 | WO2009111635A2 Dithiol compounds, derivatives, and uses therefor |
| 09/11/2009 | WO2009111633A2 Mercaptan and seleno-mercaptan compounds and methods of using them |
| 09/11/2009 | WO2009111623A2 Amorphous varenicline tartrate |
| 09/11/2009 | WO2009111611A2 Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes |
| 09/11/2009 | WO2009111607A1 Hydroxyalkanyl amides as modulators of chemokine receptor activity |
| 09/11/2009 | WO2009111603A2 Deitary supplement for eye health |
| 09/11/2009 | WO2009111576A2 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| 09/11/2009 | WO2009111574A2 BISMETHYLENE-17α CARBOLACTONES AND RELATED USES |
| 09/11/2009 | WO2009111565A2 Use of lipoxins to counteract the impact of anesthetic on inflammatory resolution |
| 09/11/2009 | WO2009111555A1 Combination treatment for bladder cancer comprisining valrubicin and trospium chloride |
| 09/11/2009 | WO2009111550A1 Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloal kanes |
| 09/11/2009 | WO2009111547A1 7h-pyrrolo[2,3-h]quinazoline compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis |
| 09/11/2009 | WO2009111543A2 Treatment of hearing and balance impairments with redox-active therapeutics |
| 09/11/2009 | WO2009111531A1 Pyrrolotriazine kinase inhibitors |
| 09/11/2009 | WO2009111530A2 Use of lipoxins to counteract the impact of anesthetic on inflammatory resolution |
| 09/11/2009 | WO2009111502A2 Anti-cancer compounds, synthesis thereof, and methods of using same |
| 09/11/2009 | WO2009111501A1 Derivatives of imidazo [4, 5-d] pyridazine and their use as anti-viral compounds |
| 09/11/2009 | WO2009111449A1 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists |
| 09/11/2009 | WO2009111444A1 Modulation of srpx2-mediated angiogenesis |
| 09/11/2009 | WO2009111442A1 AMINO-QUINOXALINE AND AMINO-QUINOLINE COMPOUNDS FOR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| 09/11/2009 | WO2009111422A2 Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens |
| 09/11/2009 | WO2009111418A2 Ketorolac tromethamine compositions for treating or preventing ocular pain |
| 09/11/2009 | WO2009111417A1 Substituted beta-lactams |
| 09/11/2009 | WO2009111375A2 Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas |
| 09/11/2009 | WO2009111354A2 Tyrosine kinase inhibitors |
| 09/11/2009 | WO2009111337A1 Compounds and compositions as tlr activity modulators |
| 09/11/2009 | WO2009111322A1 Substituted cyclopentanes having prostaglandin activity |
| 09/11/2009 | WO2009111280A1 N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
| 09/11/2009 | WO2009111279A1 Pyrazole [3, 4-b] pyridine raf inhibitors |
| 09/11/2009 | WO2009111278A2 Raf inhibitor compounds and methods of use thereof |
| 09/11/2009 | WO2009111277A1 Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors |
| 09/11/2009 | WO2009111264A2 Systemic purine administration:modulating axonal outgrowth of central nervous system neurons |